Embecta Corp.
Embecta Corp. (EMBC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
embc · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Embecta Corp. (EMBC) measures how much investors pay for each dollar of the company's trailing earnings. EMBC's current PE ratio of 1.76x is calculated by dividing its stock price of $3.33 by its TTM earnings per share of $1.92. −80.6% discount vs 5Y avg 9.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 7 fiscal years · Front-end computedMinQ1 · 25%7.3x
MedianQ3 · 75%12.2x
Max
At 1.76x, EMBC's current P/E is lower than in 0% of its annual fiscal year readings over the past 7 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Embecta Corp.You EMBC | $198M | 1.76x | — | $1.92 |
 Aquestive Therapeutics, Inc. AQST | $389M | N/A | — | -$0.69 |
 CareDx, Inc CDNA | $1.1B | N/A | — | -$0.40 |
 Emergent BioSolutions Inc. EBS | $421M | 12.57x | — | $0.98 |
 Evolent Health, Inc. EVH | $542M | N/A | — | -$4.68 |
 Maravai LifeSciences Holdings, Inc. MRVI | $1.4B | N/A | — | -$0.90 |
 Myriad Genetics, Inc. MYGN | $418M | N/A | — | -$3.92 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | 8.62x | $1.64 | -18.0% | |
2024-09-30 FY2024 | 10.52x | $1.34 | -14.0% | |
2023-09-30 FY2023 | 12.24x | $1.23 | +66.6% | |
2022-09-30 FY2022 | 7.35x | $3.92 | +14.1% | |
2021-09-30 FY2021 | 6.44x | $7.30 | +2.7% | |
2020-09-30 FY2020 | 6.27x | $7.50 | +1.0% | |
2019-09-30 FY2019 | 6.20x | $7.58 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Embecta Corp. (EMBC) measures how much investors pay for each dollar of the company's trailing earnings. EMBC's current PE ratio of 1.76x is calculated by dividing its stock price of $3.33 by its TTM earnings per share of $1.92.
Frequently asked questions
EMBC pe ratio · 6 questionsEMBC's current PE ratio is 1.76x as of 2026-06-08, based on a stock price of $3.33 and TTM EPS of $1.92. Data sourced from Financial Modeling Prep via EMBC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Embecta Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08